📣 VC round data is live. Check it out!

Oncology Institute Valuation Multiples

Discover revenue and EBITDA valuation multiples for Oncology Institute and similar public comparables like Cross Country Healthcare, LNA Sante, Propel Funeral Partners, Oceania Healthcare and more.

Oncology Institute Overview

About Oncology Institute

The Oncology Institute Inc offers oncology services committed to improving cancer prevention, diagnosis, treatment, research, and education. The company provides services including infusion centres. In-house dispensary, Outpatient blood transfusion, Outpatient stem cell transplant, financial counseling, clinical trials, comprehensive lab testing, and end-of-life counseling. The business operates in three operating segments dispensary, patients services and clinical trials and others. Key revenue is earned from providing patient services. Majority of revenue is from patients services.


Founded

2007

HQ

United States

Employees

825

Financials (LTM)

Revenue: $564M
EBITDA: ($6M)

EV

$534M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Oncology Institute Financials

Oncology Institute reported last 12-month revenue of $564M and negative EBITDA of ($6M).

In the same LTM period, Oncology Institute generated $87M in gross profit, ($6M) in EBITDA losses, and had net loss of ($37M).

Revenue (LTM)


Oncology Institute P&L

In the most recent fiscal year, Oncology Institute reported revenue of $503M and EBITDA of ($12M).

Oncology Institute is unprofitable as of last fiscal year, with gross margin of 15%, EBITDA margin of (2%), and net margin of (10%).

See analyst estimates for Oncology Institute
LTMLast FY202320242025202620272028
Revenue$564M$503M$324M$393M$503M
Gross Profit$87M$76M$60M$54M$76M
Gross Margin16%15%18%14%15%
EBITDA($6M)($12M)($70M)($51M)($43M)
EBITDA Margin(1%)(2%)(22%)(13%)(8%)
EBIT Margin(5%)(7%)(19%)(15%)(7%)
Net Profit($37M)($50M)($83M)($65M)($61M)
Net Margin(7%)(10%)(26%)(16%)(12%)
Net Debt—$44M———

Financial data powered by Morningstar, Inc.

Oncology Institute Stock Performance

Oncology Institute has current market cap of $459M, and enterprise value of $534M.

Market Cap Evolution


Oncology Institute's stock price is $4.59.

Oncology Institute share price increased by 18.7% in the last 30 days, and by 44.0% in the last year.

Oncology Institute has an EPS (earnings per share) of $-0.50.

See more trading valuation data for Oncology Institute
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$534M$459M0.0%18.7%59.8%44.0%$-0.50

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Oncology Institute Valuation Multiples

Oncology Institute trades at 0.9x EV/Revenue multiple, and (94.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Oncology Institute

EV / Revenue (LTM)


Oncology Institute Financial Valuation Multiples

As of May 26, 2026, Oncology Institute has market cap of $459M and EV of $534M.

Oncology Institute has a P/E ratio of (12.3x).

LTMLast FY202320242025202620272028
EV/Revenue0.9x1.1x1.6x1.4x1.1x
EV/EBITDA(94.3x)(43.0x)(7.6x)(10.5x)(12.6x)
EV/EBIT(19.5x)(14.8x)(8.9x)(8.9x)(14.8x)
EV/Gross Profit6.1x7.0x9.0x9.9x7.0x
P/E(12.3x)(9.1x)(5.5x)(7.1x)(7.6x)
EV/FCF(22.4x)(22.4x)(13.1x)(17.6x)(19.2x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Oncology Institute Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Oncology Institute Margins & Growth Rates

Oncology Institute grew revenue by 30% but EBITDA decreased by 136% in the last fiscal year.

In the most recent fiscal year, Oncology Institute reported gross margin of 15%, EBITDA margin of (2%), and net margin of (10%).

See estimated margins and future growth rates for Oncology Institute

Oncology Institute Margins

Last FY202420252026202720282029
Gross Margin15%14%15%16%
EBITDA Margin(2%)(13%)(8%)1%
EBIT Margin(7%)(15%)(7%)(2%)
Net Margin(10%)(16%)(12%)(3%)
FCF Margin(5%)(8%)(6%)—

Oncology Institute Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth30%21%28%30%
Gross Profit Growth36%(9%)42%36%
EBITDA Growth(136%)(28%)(16%)(110%)
EBIT Growth(61%)(0%)(40%)(61%)
Net Profit Growth(64%)(22%)(6%)(70%)
FCF Growth—(26%)(8%)—

Data powered by FactSet, Inc. and Morningstar, Inc.

Oncology Institute Operational KPIs

Oncology Institute's revenue per employee in the last FY averaged $0.6M, while opex per employee averaged $0.1M for the same period.

Oncology Institute's Rule of 40 is 31% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Oncology Institute's Rule of X is 76% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Oncology Institute
LTMLast FY202320242025202620272028
Rule of 4027%31%———
Bessemer Rule of X69%76%———
Revenue per Employee—$0.6M———
Opex per Employee—$0.1M———
Opex to Revenue—22%37%29%22%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Oncology Institute Competitors

Oncology Institute competitors include Cross Country Healthcare, LNA Sante, Propel Funeral Partners, Oceania Healthcare, Enhabit, Eureka Group Holdings, Joint, Radius Residential, DocGo and InnovAge.

Most Oncology Institute public comparables operate across Long-Term Care.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Cross Country Healthcare0.3x0.3x11.2x11.4x
LNA Sante1.2x1.2x7.4x8.0x
Propel Funeral Partners3.0x2.9x12.4x11.3x
Oceania Healthcare4.4x3.3x16.8x16.6x
Enhabit—1.1x—10.6x
Eureka Group Holdings7.9x7.2x10.8x18.0x
Joint2.0x1.9x8.4x8.7x
Radius Residential1.8x1.5x10.4x8.7x

This data is available for Pro users. Sign up to see all Oncology Institute competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Oncology Institute

When was Oncology Institute founded?Oncology Institute was founded in 2007.
Where is Oncology Institute headquartered?Oncology Institute is headquartered in United States.
How many employees does Oncology Institute have?As of today, Oncology Institute has over 825 employees.
Who is the CEO of Oncology Institute?Oncology Institute's CEO is Daniel Virnich.
Is Oncology Institute publicly listed?Yes, Oncology Institute is a public company listed on Nasdaq.
What is the stock symbol of Oncology Institute?Oncology Institute trades under TOI ticker.
When did Oncology Institute go public?Oncology Institute went public in 2021.
Who are competitors of Oncology Institute?Oncology Institute main competitors include Cross Country Healthcare, LNA Sante, Propel Funeral Partners, Oceania Healthcare, Enhabit, Eureka Group Holdings, Joint, Radius Residential, DocGo, InnovAge.
What is the current market cap of Oncology Institute?Oncology Institute's current market cap is $459M.
What is the current revenue of Oncology Institute?Oncology Institute's last 12 months revenue is $564M.
What is the current revenue growth of Oncology Institute?Oncology Institute revenue growth (NTM/LTM) is 28%.
What is the current EV/Revenue multiple of Oncology Institute?Current revenue multiple of Oncology Institute is 0.9x.
Is Oncology Institute profitable?No, Oncology Institute is not profitable.
What is the current EBITDA of Oncology Institute?Oncology Institute has negative EBITDA and is not profitable.
What is Oncology Institute's EBITDA margin?Oncology Institute's last 12 months EBITDA margin is (1%).
What is the current EV/EBITDA multiple of Oncology Institute?Current EBITDA multiple of Oncology Institute is (94.3x).
What is the current FCF of Oncology Institute?Oncology Institute's last 12 months FCF is ($24M).
What is Oncology Institute's FCF margin?Oncology Institute's last 12 months FCF margin is (4%).
What is the current EV/FCF multiple of Oncology Institute?Current FCF multiple of Oncology Institute is (22.4x).
How many companies Oncology Institute has acquired to date?Oncology Institute hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Oncology Institute has invested to date?Oncology Institute hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Oncology Institute

Lists including Oncology Institute

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial